OCT 2·SEC EDGARLow
Cavers Greg purchased $39K of HELP (indirect holdings)
Cavers Greg (Chief Financial Officer) purchased 3,000 indirectly-held shares of Helus Pharma Inc. (HELP) at $12.91 on 2026-09-29.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$HELP
CYBIN INC.
Price · $HELPvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 1
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $7.5M 7 txs
- Sells
- — 0 txs
Glavine Paul3× · $3.7M
10b5-1 share of filings0%
Top stories · $HELPMore →
OCT 1·investing.com
Cybin rebrands to Helus Pharma, ticker symbol unchanged
Cybin Inc. has legally changed its name to Helus Pharma Inc. The rebrand, approved by shareholders, reflects the company's transition to a commercial-ready pharmaceutical firm. Shares will continue trading on Nasdaq and Cboe Canada under the ticker HELP. The company is developing serotonergic agonists for mental health disorders, with HLP003 in Phase 3 trials for major depressive disorder.
SEP 26·tipranks.com
Nutanix, Star Bulk, Lennar, Hershey, Helus Insider Shock
Insiders traded shares in five companies: Nutanix's president sold $4.76M shares, Star Bulk directors sold $435.82K, Berkshire Hathaway bought $348.78M Lennar shares, Hershey Trust sold $5.05M, and Helus Pharma's CEO bought $1.35M.
HELP sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HELP (CYBIN INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent HELP coverage spans insider activity, corporate actions and financial news.
In the last 30 days, HELP insiders filed 7 SEC Form 4 transactions — 7 purchases ($7.5M) and no sales. The most active reporter was Glavine Paul, Chief Growth Officer, with 3 filings.
What's driving HELP
Insider purchase may signal confidence, creating modest upward pressure.
The name change is a corporate action with minimal immediate financial impact.
Positive sentiment from insider purchase.
Potential branding shift and new board composition could affect corporate strategy and stock perception.
Potential upside if price moves toward target.
AlphAI scores every news story that mentions HELP with an AI model for sentiment and relevance, and aggregates insider trades from CYBIN INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $HELP
Score
Cavers Greg purchased $39K of HELP (indirect holdings)
Cavers Greg (Chief Financial Officer) purchased 3,000 indirectly-held shares of Helus Pharma Inc. (HELP) at $12.91 on 2026-09-29.
1 min readCybin rebrands to Helus Pharma, ticker symbol unchanged
Cybin Inc. has legally changed its name to Helus Pharma Inc. The rebrand, approved by shareholders, reflects the company's transition to a commercial-ready pharmaceutical firm. Shares will continue trading on Nasdaq and Cboe Canada under the ticker HELP. The company is developing serotonergic agonists for mental health disorders, with HLP003 in Phase 3 trials for major depressive disorder.
1 min read
Nutanix, Star Bulk, Lennar, Hershey, Helus Insider Shock
Insiders traded shares in five companies: Nutanix's president sold $4.76M shares, Star Bulk directors sold $435.82K, Berkshire Hathaway bought $348.78M Lennar shares, Hershey Trust sold $5.05M, and Helus Pharma's CEO bought $1.35M.
2 min read
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
Cybin Inc. shareholders voted on a name change to Helus Pharma, which requires two-thirds support. The company nominated eight directors, including CEO Michael Halstead. Voting results will be published post-meeting. Cybin focuses on psychedelic-based therapeutics for mental health conditions, with programs like CYB003 and CYB004.
1 min read
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)
Analysts from Barclays and Bank of America updated ratings for healthcare companies. Helus Pharma (HELP) and Ultragenyx Pharmaceutical (RARE) both received Buy ratings with $35 price targets. Novavax (NVAX) was rated Sell with a $7 target. Current prices and analyst consensus targets were also provided.
2 min readHalstead Michael purchased $1.3M of HELP
Halstead Michael (Chief Executive Officer) purchased 100,000 shares of CYBIN INC. (HELP) at $13.47 ($1.35M total) on 2026-09-21.
1 min readHELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results
Helus Pharma (HELP) shares rose to a 52-week high of $15.15 before falling 11% after Barclays initiated coverage with an Overweight rating and $35 price target. The company awaits Q4 trial results for its psychedelic drug HLP003, with FDA Breakthrough Therapy status. Analysts' average price target is $41.40, implying 195% upside. HELP has gained 53% year-to-date.
2 min readGlavine Paul purchased $1.2M of HELP
Glavine Paul (Chief Growth Officer) purchased 100,000 shares of CYBIN INC. (HELP) at $12.47 ($1.25M total) on 2026-09-08.
1 min readGlavine Paul purchased $1.2M of HELP
Glavine Paul (Chief Growth Officer) purchased 100,000 shares of CYBIN INC. (HELP) at $12.47 ($1.25M total) on 2026-09-08.
1 min readSo Eric H. L. purchased $1.2M of HELP
So Eric H. L. (Executive Chair) purchased 100,000 shares of CYBIN INC. (HELP) at $12.39 ($1.24M total) on 2026-09-08.
1 min read